June Lu
Chief Scientific OfficerDr. June Lu Ph.D is Chief Scientific Officer of BeyondSpring Inc. since April 1, 2024. Dr. Lu joined the BeyondSpring Inc. on March 31, 2024 and was its Executive Director of Transitional Medicine. Dr. Lu has led cross-functional project teams to develop small molecule-based strategies for cancer (FolateImmune; bispecific CAR-T cell therapy) and autoimmunity (DHFR/mTOR inhibitors). In addition, she has spearHeaded deep-dive scientific efforts in macrophage-targeting, drug resistance & IO (PD-1/CTLA-4) combinations, target ID/pre-validation and indication selections. She has authored about 30 peer-reviewed publications and is an inventor for multiple patents. Dr. Lu has Ph.D. in Chemistry from Purdue University. Dr. Lu has B. S. in Analytical Chemistry from Zhejiang University of Technology. Dr. Lu worked at Endocyte, which developed 177Lu-PSMA-617, now approved drug Pluvicto® and at Advanced Accelerator Applications, a Novartis company and Novartis Institute for Biomedical Research.
Positions
- Company NameBeyondSpring Inc.Stock CodeBYSIPositionChief Scientific OfficerColleagues
- LHLan HuangCo-Founder & Chair of the Board
- MQMin QiuChief Executive Officer
- LNLi NaChief Financial Officer
- SKStephen KilmerHead of Investor Relations
- JMJiangwen MajetiIndependent Vice Chairman
- MKMatthew KirkbyIndependent Director
- PFPatrick FabbioIndependent Director
- DWDouglas W. BlayneyMember of Scientific Advisors & Principal Investigators Board
